[
  {
    "quarter": "2020_Q2",
    "analyst_name": "Matt Taylor",
    "analyst_name_GT": "Matt Taylor",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hi, thank you for taking the question. So I appreciate all the detail on June and July. This is more than we've gotten from a lot of other companies. And I guess I'm just wondering if your positivity on July is, you think, differentially related to your portfolio, your products, your exposures, or Are we seeing just the benefit of having more hindsight, and do you think that we're seeing more broad recovery through the month for the MedTech space?",
    "quoted_compliment_GT": "Hi, thank you for taking the question. So I appreciate all the detail on June and July. This is more than we've gotten from a lot of other companies. And I guess I'm just wondering if your positivity on July is, you think, differentially related to your portfolio, your products, your exposures, or Are we seeing just the benefit of having more hindsight, and do you think that we're seeing more broad recovery through the month for the MedTech space? Okay. And one follow-up, you know, in the supplemental presentation and the prepared commentary, you talked about being able to resume a normal pace of account openings for Lotus and restarting a lot of your clinical trial activities. So that also seems encouraging. And I guess I was just hoping to get some color on how you're able to do that with the COVID flare-ups because, you know, that does â€“ kind of fly in the face of it, but it seems like you're optimistic you'll be returning to a more normal pace here. ____ ",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q2",
    "analyst_name": "Joanne Wunsch",
    "analyst_name_GT": "Joanne Wunsch",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hi, can you hear me okay?",
    "quoted_compliment_GT": "Hi, can you hear me okay? Excellent. Good morning, and thank you for taking the question. It looked to us like when we compared the delivery versus consensus, there's two areas that might be lagging a little bit, our EP and CRM. But I also remember that there are a number of key products in those sections. Can you highlight one or two that might bring you back into sort of the market taker or gain position? Thank you. And my second question also is product-related. If I had to say to you what are the three products you want us to focus on over the next six to 12 months, what would your answer be? Thank you so much. ____ Hi, can you hear me okay?",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q2",
    "analyst_name": "Travis Steed",
    "analyst_name_GT": "Travis Steed",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hi. Good morning. Thanks for the question. I appreciate some of the longer-term comments you gave on operating margins. Just curious what the base we should be using for that 50%. our 50 basis points of margin expansion per year, if we should think about that 26% in the back half here. So thinking about the street somewhere in 26 and a half percent, next year would be a reasonable place to be at this point.",
    "quoted_compliment_GT": "Hi. Good morning. Thanks for the question. I appreciate some of the longer-term comments you gave on operating margins. Just curious what the base we should be using for that 50%. our 50 basis points of margin expansion per year, if we should think about that 26% in the back half here. So thinking about the street somewhere in 26 and a half percent, next year would be a reasonable place to be at this point. Okay, great. Thank you. ____ Hi. Good morning. Thanks for the question.",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q3",
    "analyst_name": "Bob Hopkins",
    "analyst_name_GT": "Bob Hopkins",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Yeah, makes sense. And then just one quick follow-up on that. I guess taking a step back, one of the things that's giving a lot of MedTech investors pause right now is just the sheer number of macro issues to kind of think through from staffing, to COVID waves, to supply chain, to inflation. And that's before we even start to look at company fundamentals. So I guess one big picture question I'd ask you, Mike, is, you know, all that's making it kind of hard for investors to know how to think about modeling for, you know, the next 12 months. And so I just would love your kind of top down thoughts on the ability of Boston to deliver over the next 12 months, you know, given all these headwinds, you know, not asking for specific quantification of things, but just your ability to manage through all these headwinds.",
    "quoted_compliment_GT": "Hi, thank you, and can you hear me okay? Thanks. Oh, great. Good morning. Thank you. So first question is pretty straightforward. I'm just curious how your thoughts on Q4 have evolved since the analyst day and what you're seeing today in terms of procedure volumes, you know, especially in the U.S.? ? Great. Appreciate the thoughts. Thank you.____",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q3",
    "analyst_name": "Matthew O'Brien",
    "analyst_name_GT": "Matthew O'Brien",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Good morning. Thanks for taking the questions. Um, Mike, as I look across the portfolio, I think a lot of things held up better than I might've expected going into Q3 with all these, these COVID headwinds, you know, with, with their sphere doing better and peripheral and, and, um, uh, preventive seeming to hold up, you know, CRM and Watchman obviously doing well, even when netting out the, um, the reserve tailwind. So what I'm curious about is what you're seeing in non COVID geographies, as far as the momentum in those businesses, You know, are you taking share with some of these new products? Are you seeing accelerating momentum with some of these new categories? And why wouldn't that accelerate coming out of COVID just given, you know, some of the underlying strength that I think is there?",
    "quoted_compliment_GT": "Good morning. Thanks for taking the questions. Um, Mike, as I look across the portfolio, I think a lot of things held up better than I might've expected going into Q3 with all these, these COVID headwinds, you know, with, with their sphere doing better and peripheral and, and, um, uh, preventive seeming to hold up, you know, CRM and Watchman obviously doing well, even when netting out the, um, the reserve tailwind. So what I'm curious about is what you're seeing in non COVID geographies, as far as the momentum in those businesses, You know, are you taking share with some of these new products? Are you seeing accelerating momentum with some of these new categories? And why wouldn't that accelerate coming out of COVID just given, you know, some of the underlying strength that I think is there? Got it. Thank you.____",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q4",
    "analyst_name": "Matt Mixick",
    "analyst_name_GT": "Matt Mixick",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hi, good morning. Thanks for taking the question. So I had one follow-up on some of the portfolio and investment and strategic comments that you made regarding Millipede and sort of the other options that are out there. If you could talk maybe a little bit about one of the areas I don't think you mentioned was tricuspid and other sort of structural heart opportunities as well as digital and any understanding heart logic is a big part of your CRM strategy. Maybe if you could comment on further investments there or to what degree you view either one of those as strategically important and I had one follow-up if I could.",
    "quoted_compliment_GT": "Hi, good morning. Thanks for taking the question. So I had one follow-up on some of the portfolio and investment and strategic comments that you made regarding Millipede and sort of the other options that are out there. If you could talk maybe a little bit about one of the areas I don't think you mentioned was tricuspid and other sort of structural heart opportunities as well as digital and any understanding heart logic is a big part of your CRM strategy. Maybe if you could comment on further investments there or to what degree you view either one of those as strategically important and I had one follow-up if I could. Okay, great. And then just one follow-up. You have obviously a lot of strong growth drivers contributing, you know, currently in Q4, but importantly throughout, you know, 2022, you have this cadence of new acquisitions that are kind of rolling in. You mentioned, you know, the 200 basis points contribution to reported not organic in Q1. Can you maybe just give us a thumbnail sketch of how the you know, quarter to quarter, you know, what those additional acquisitions will look like in terms of additive organic growth throughout the year, that'd be super. Great, thanks so much. ____ ",
    "partial_name_match": false
  },
  {
    "quarter": "2021_Q4",
    "analyst_name": "Cecilia Furlong",
    "analyst_name_GT": "Cecilia Furlong",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Great. Thank you for taking the questions. I wanted to ask just on your EP business specifically, can you talk about what you're seeing in Europe just in terms of early Farrah Pulse versus Cryo versus RF trends? And then just beyond that as well, can you provide an update on your Farrah Pulse US trial, where enrollment stands there? as well as what you're seeing in Japan, specifically around PolarX. Thank you.",
    "quoted_compliment_GT": "Great. Thank you for taking the questions. I wanted to ask just on your EP business specifically, can you talk about what you're seeing in Europe just in terms of early Farrah Pulse versus Cryo versus RF trends? And then just beyond that as well, can you provide an update on your Farrah Pulse US trial, where enrollment stands there? as well as what you're seeing in Japan, specifically around PolarX. Thank you. ____ ",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q2",
    "analyst_name": "Joanne Lynch",
    "analyst_name_GT": "Joanne Lynch",
    "level": 0,
    "level_GT": 1,
    "quoted_compliment": "Good morning, and thank you for taking the question. May I say congratulations? I want to spend just a little bit of time on the organic growth rate, because when you entered the year, we were looking for 6% to 8%, which was raised on the first quarter call to 6.5% to 8.5%, and now to 8% to 9% organic. What is happening in your core businesses or in your particular franchises, maybe, that's helping you sort of buck the trend and actually be raising your organic growth rate each quarter?",
    "quoted_compliment_GT": "Good morning, and thank you for taking the question. May I say congratulations? What is happening in your core businesses or in your particular franchises, maybe, that's helping you sort of buck the trend and actually be raising your organic growth rate each quarter? ____ May I say congratulations?",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q3",
    "analyst_name": "Travis Seed",
    "analyst_name_GT": "Travis Seed",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hey, thanks for taking the question, and also congrats to Ian Meredith. I might have missed it earlier, but can you remind us again the moving parts on what drove the higher OPX and the lower margin guide for 2022 versus three months ago, just as a quick clarification? And then the question I was going to ask was more on the analyst day last year, you were committed to a double-digit EPS growth CAGR. This year, you're close to 7%. Is that double-digit EPS CAGR still good and the starting point for 2023? and still be in that double-digit range given the macro pressures that we're in?",
    "quoted_compliment_GT": "Hey, thanks for taking the question, and also congrats to Ian Meredith. I might have missed it earlier, but can you remind us again the moving parts on what drove the higher OPX and the lower margin guide for 2022 versus three months ago, just as a quick clarification? And then the question I was going to ask was more on the analyst day last year, you were committed to a double-digit EPS growth CAGR. This year, you're close to 7%. Is that double-digit EPS CAGR still good and the starting point for 2023? and still be in that double-digit range given the macro pressures that we're in? Great. And congrats on a good top line. Thanks. ____ congrats to Ian Meredith.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q3",
    "analyst_name": "Matthew O'Brien",
    "analyst_name_GT": "Matthew O'Brien",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Good morning. Thanks for taking the question and let me offer my congratulations to Dr. Meredith as well on his retirement. You know, Mike, it seems like you're taking a little bit of near-term, you know, pain right now to continue your spending, you know, in these growth areas because you continue to be one of the faster growth diversified med tech names out there. So I'm just curious, You know, if you feel like that momentum is going to continue into 23 where you can stay one of the faster growth large cap med tech names out there, and if it's going to be more of a broad-based, you know, level of improvement across all the different franchises where you can keep kind of growing in this double-digit range in some areas, or if it's going to be a little bit more focal than what we've seen historically. I don't know if it's specifically in cardiology or other areas. Thank you.",
    "quoted_compliment_GT": "Good morning. Thanks for taking the question and let me offer my congratulations to Dr. Meredith as well on his retirement. You know, Mike, it seems like you're taking a little bit of near-term, you know, pain right now to continue your spending, you know, in these growth areas because you continue to be one of the faster growth diversified med tech names out there. So I'm just curious, You know, if you feel like that momentum is going to continue into 23 where you can stay one of the faster growth large cap med tech names out there, and if it's going to be more of a broad-based, you know, level of improvement across all the different franchises where you can keep kind of growing in this double-digit range in some areas, or if it's going to be a little bit more focal than what we've seen historically. I don't know if it's specifically in cardiology or other areas. Thank you. ____ ''",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Joanne Lynch",
    "analyst_name_GT": "Joanne Lynch",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Thank you very much for taking the question, and good morning. I want to spend just a minute or two on urology and pelvic health business. I mean, that was a another 12% this quarter, 12.7% organically last quarter. What is driving that, and should we think of this more as a solid double-digit grower as we look forward? And my follow-up question, I'm going to just put it out there now, 50 basis points of operating margin expansion, or at least 50 basis points this year, where is that coming from? Thank you.",
    "quoted_compliment_GT": "Thank you very much for taking the question, and good morning. I want to spend just a minute or two on urology and pelvic health business. I mean, that was a another 12% this quarter, 12.7% organically last quarter. What is driving that, and should we think of this more as a solid double-digit grower as we look forward? And my follow-up question, I'm going to just put it out there now, 50 basis points of operating margin expansion, or at least 50 basis points this year, where is that coming from? Thank you.____Thank you.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Vijay Kumar",
    "analyst_name_GT": "Vijay Kumar",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hey, guys. Thanks for taking my question. Just some cleanup questions here on the guidance assumptions. Mike, the 68% organic, it is what it is, but can you just remind us, you know, what are the incremental tailwinds, positive tailwinds here in 23 and any incremental headwinds versus 22? You know, some things I can think of, the FaroPulse becomes organic, maybe China has a little bit of headwind, but can you just go through some of those drivers? And Dan, on, you know, share count up, you know, 20 million, that seems egregious just given how we've seen share count progress throughout the year. I'm curious why and what's behind the share count assumptions of the year.",
    "quoted_compliment_GT": "Hey, guys. Thanks for taking my question. Just some cleanup questions here on the guidance assumptions. Mike, the 68% organic, it is what it is, but can you just remind us, you know, what are the incremental tailwinds, positive tailwinds here in 23 and any incremental headwinds versus 22? You know, some things I can think of, the FaroPulse becomes organic, maybe China has a little bit of headwind, but can you just go through some of those drivers? And Dan, on, you know, share count up, you know, 20 million, that seems egregious just given how we've seen share count progress throughout the year. I'm curious why and what's behind the share count assumptions of the year.____That's helpful, yes.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Cecilia Furlong",
    "analyst_name_GT": "Cecilia Furlong",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Great. Good morning, and thank you for taking the question. I wanted to ask on Watchman. Specifically, what's underlying the double-digit growth outlook that you called out for 23? How are you thinking about market growth as well as Japan and China contributions? And then just a quick follow-up on AccurateNEO2 with the Prime XL registry. How are you thinking about approval timelines at this point in the U.S.?",
    "quoted_compliment_GT": "Great. Good morning, and thank you for taking the question. I wanted to ask on Watchman. Specifically, what's underlying the double-digit growth outlook that you called out for 23? How are you thinking about market growth as well as Japan and China contributions? And then just a quick follow-up on AccurateNEO2 with the Prime XL registry. How are you thinking about approval timelines at this point in the U.S.?____Thank you for taking the questions.",
    "partial_name_match": false
  },
  {
    "quarter": "2022_Q4",
    "analyst_name": "Josh Jennings",
    "analyst_name_GT": "Josh Jennings",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hi. Good morning. Thanks for taking the questions. I was hoping to start off with just your Apollo acquisition. gets you into the diabetes, sorry, diabetes, the obesity segment. And just wanted to hear about your outlook for that portfolio, but also just a device-based intervention opportunities in obesity from a higher level and whether this portfolio could become a long-term growth driver for the endoscopy franchise. Then the follow-up is just on your neuromyelodulation business. Congratulations on the solace trial results and, uh, I think three of the big competitors in the space have a peripheral diabetic neuropathy indication now with different levels of evidence. But I was hoping you could just review Boston's plan to generate clinical evidence for that indication going forward. Thanks a lot.",
    "quoted_compliment_GT": "Hi. Good morning. Thanks for taking the questions. I was hoping to start off with just your Apollo acquisition. gets you into the diabetes, sorry, diabetes, the obesity segment. And just wanted to hear about your outlook for that portfolio, but also just a device-based intervention opportunities in obesity from a higher level and whether this portfolio could become a long-term growth driver for the endoscopy franchise. Then the follow-up is just on your neuromyelodulation business. Congratulations on the solace trial results and, uh, I think three of the big competitors in the space have a peripheral diabetic neuropathy indication now with different levels of evidence. But I was hoping you could just review Boston's plan to generate clinical evidence for that indication going forward. Thanks a lot.____",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q1",
    "analyst_name": "Matt Taylor",
    "analyst_name_GT": "Matt Taylor",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Good morning. Thanks for taking the question. So, great result. I guess what I'm struggling to understand is, you know, obviously you saw strong demand in the quarter, and I think we're seeing a lot of macro things improving, like staffing, et cetera. I mean, couldn't it actually theoretically get better sequentially? Why are we thinking so conservatively? Do you think that the direction of travel could be positive, negative, or neutral? And what are some of the background thoughts that you would base that on?",
    "quoted_compliment_GT": "Good morning. Thanks for taking the question. So, great result. I guess what I'm struggling to understand is, you know, obviously you saw strong demand in the quarter, and I think we're seeing a lot of macro things improving, like staffing, et cetera. I mean, couldn't it actually theoretically get better sequentially? Why are we thinking so conservatively? Do you think that the direction of travel could be positive, negative, or neutral? And what are some of the background thoughts that you would base that on? Yeah, and then, Mike, just to follow up on that, I mean, thinking ahead to 2024, you know, if we do have some, let's call it supernormal growth this year, some catch-up or whatever, do you still think that you can grow in kind of the LRP range in 2024 over, you know, what could be a tough comp in 2023 if things play out well? Okay. I'll be there. Thanks, Ken. ____ Good morning.",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q3",
    "analyst_name": "Matthew O'Brien",
    "analyst_name_GT": "Matthew O'Brien",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Morning, thanks for squeezing me in here. I know you guys are a domestic company, but the performance in EMEA and APAC specifically were notable, and specifically APAC was really, really strong this quarter. Can you just give us a little more sense for, because I think those two collectively were roughly after growth this quarter. The durability of the performance in those geographies, is it a function of just more and more products into those areas? And so, you know, that's pretty straightforward. Or is it share taking that's required or what's really required to continue to deliver? Maybe not this level of growth, which is really strong again, but a very strong growth going forward where that's, you know, a significant contributor to the top line for 24, 25 and beyond. Thanks.",
    "quoted_compliment_GT": "Morning, thanks for squeezing me in here. I know you guys are a domestic company, but the performance in EMEA and APAC specifically were notable, and specifically APAC was really, really strong this quarter. Can you just give us a little more sense for, because I think those two collectively were roughly after growth this quarter. The durability of the performance in those geographies, is it a function of just more and more products into those areas? And so, you know, that's pretty straightforward. Or is it share taking that's required or what's really required to continue to deliver? Maybe not this level of growth, which is really strong again, but a very strong growth going forward where that's, you know, a significant contributor to the top line for 24, 25 and beyond. Thanks.____",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q4",
    "analyst_name": "Danielle Antelfi",
    "analyst_name_GT": "Danielle Antelfi",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hey, good morning, everyone. Thanks so much for taking the question. Just a follow-up question on Accurate Neo2, Mike, if I could. So, appreciate the comments that you did provide. Just curious, I mean, obviously, you're giving pretty strong guidance here for 2024. I mean, is the right read here that regardless of what happens with Accurate Neo2 and timing there, You're sticking to your long-term sales growth guidance that you provided back in September. And sort of how do we think about this as a long-term growth contributor now given this little wrinkle here? And, Lauren, we will miss you very much. Thanks so much.",
    "quoted_compliment_GT": "Hey, good morning, everyone. Thanks so much for taking the question. Just a follow-up question on Accurate Neo2, Mike, if I could. So, appreciate the comments that you did provide. Thanks so much, guys.____Hey, good morning, everyone. Thanks so much for taking the question.",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q4",
    "analyst_name": "Josh Jennings",
    "analyst_name_GT": "Josh Jennings",
    "level": 0,
    "level_GT": 1,
    "quoted_compliment": "",
    "quoted_compliment_GT": "Good morning. Thanks for taking the questions and congratulations for a strong end of the year. Wanted to ask about the international cardiac ablation market. Boston's incredible fourth quarter 40 plus percent growth. Thanks for taking the question.____Good morning. Thanks for taking the questions and congratulations for a strong end of the year.",
    "partial_name_match": false
  },
  {
    "quarter": "2023_Q4",
    "analyst_name": "Patrick Wood",
    "analyst_name_GT": "Patrick Wood",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Amazing. Thank you for taking the question, and congrats, Lauren. I might stick with Axonix if that's all right. I appreciate it hasn't closed yet, but I'm just kind of curious, you know, urology in Boston has a very sizable distribution network across, I guess, primarily stone management, but a whole bunch of different areas. How are you thinking about, you know, the ability to drive adoption in OAB faster and, like, really push that asset? I'm guessing, you know, having just played with the numbers, and correct me if I'm wrong, but there's some assumption of slightly faster growth there. Once you've acquired Axonics and the street previously had in there, at least that's where I end up with the numbers. Feel free to correct me, but how are you thinking about the commercialization and really pushing that through the distribution network? Thanks.",
    "quoted_compliment_GT": "Amazing. Thank you for taking the question, and congrats, Lauren. I might stick with Axonix if that's all right. I appreciate it hasn't closed yet, but I'm just kind of curious, you know, urology in Boston has a very sizable distribution network across, I guess, primarily stone management, but a whole bunch of different areas. How are you thinking about, you know, the ability to drive adoption in OAB faster and, like, really push that asset? Thanks.____Amazing. Thank you for taking the question, and congrats, Lauren.",
    "partial_name_match": false
  },
  {
    "quarter": "2024_Q2",
    "analyst_name": "Vijay Kumar",
    "analyst_name_GT": "Vijay Kumar",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hi, guys. Thanks for taking my question, and my congratulations on my experience here. I had one question on USPFA, the 220% growth. Can you parse out what was the capital contribution versus, you know, capital contribution in the U.S. number? And I think you mentioned a TPT, you know, in the U.S., in the allocation setting. Any update on has Boston submitted its TPT? Thank you.",
    "quoted_compliment_GT": "Hi, guys. Thanks for taking my question, and my congratulations on my experience here. I had one question on USPFA, the 220% growth. Can you parse out what was the capital contribution versus, you know, capital contribution in the U.S. number? And I think you mentioned a TPT, you know, in the U.S., in the allocation setting. Any update on has Boston submitted its TPT? Thank you.____Hi, guys. Thanks for taking my question, and my congratulations on my experience here.",
    "partial_name_match": false
  },
  {
    "quarter": "2024_Q3",
    "analyst_name": "Joanne Lynch",
    "analyst_name_GT": "Joanne Lynch",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Good morning, and thank you for the question. I want to talk about the amazing results of Faribault that we just saw, and specifically how you're thinking about moving, I was really interested in one quote that you said, to exceed 40 to 60% of global AF procedures by 2026. Thank you.",
    "quoted_compliment_GT": "Good morning, and thank you for the question. I want to talk about the amazing results of Faribault that we just saw, and specifically how you're thinking about moving, I was really interested in one quote that you said, to exceed 40 to 60% of global AF procedures by 2026. Thank you.____amazing results of Faribault",
    "partial_name_match": false
  },
  {
    "quarter": "2024_Q3",
    "analyst_name": "Matt Mixick",
    "analyst_name_GT": "Matt Mixick",
    "level": 0,
    "level_GT": 1,
    "quoted_compliment": "",
    "quoted_compliment_GT": "Perfect. Thank you very much for taking my question. I guess it's one on capacity and totality for the system. Obviously, I get PFA adding some efficiencies to the system overall, but for EPs, between Watchmen and everything, there's a tremendous call on people's time. Love it. Thanks for the call.____congrats on a really impressive quarter",
    "partial_name_match": false
  },
  {
    "quarter": "2024_Q3",
    "analyst_name": "Matthew O'Brien",
    "analyst_name_GT": "Matthew O'Brien",
    "level": 1,
    "level_GT": 0,
    "quoted_compliment": "Hey, thanks so much for fitting us in, and congrats on a really impressive quarter and all the great growth drivers you have running. I had a question just on, maybe for Dan, on some of the dynamics in the gross margin line in the quarter. You mentioned FX being kind of one of the primary headwinds, but as you move into 25, maybe you can talk a little bit about you know, where the leverage in the model is. It's, you know, table gross margin and levering some of the operating investments that you're making, but maybe just some color on how you see that progressing at this point. Thanks.",
    "quoted_compliment_GT": "Morning. Thanks for taking the question. And I'd much rather focus on all the positive things going on here, but I'm looking at the stock down now versus up prior to this avant-garde commentary. So, Dr. Stein, I'm not sure exactly what you can say, but is there any kind of safety signal that we should be aware of? And then if you can't comment on that, is there anything to think about in terms of this patient population really being the cause of the difference, maybe extra lesions that need to be created? um, higher risk, you know, benefit requirements because it's drug naive patients. Um, just anything along those lines that you can share, um, because I think folks are pretty nervous this morning just based on, uh, how important Ferrapulse is to the, to the business. Thanks.____",
    "partial_name_match": false
  }
]